Biotricity (NASDAQ:BTCY – Get Free Report) and Accuray (NASDAQ:ARAY – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.
Volatility & Risk
Biotricity has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Accuray has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.
Earnings & Valuation
This table compares Biotricity and Accuray”s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Biotricity | $12.06 million | 0.86 | -$14.09 million | ($1.08) | -0.39 |
Accuray | $453.14 million | 0.41 | -$15.55 million | ($0.05) | -36.40 |
Profitability
This table compares Biotricity and Accuray’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Biotricity | -80.42% | N/A | -188.47% |
Accuray | -0.96% | -9.75% | -0.93% |
Institutional and Insider Ownership
3.9% of Biotricity shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 10.1% of Biotricity shares are owned by insiders. Comparatively, 4.2% of Accuray shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Biotricity and Accuray, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Biotricity | 0 | 1 | 0 | 0 | 2.00 |
Accuray | 0 | 0 | 0 | 0 | 0.00 |
About Biotricity
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
About Accuray
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Receive News & Ratings for Biotricity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotricity and related companies with MarketBeat.com's FREE daily email newsletter.